MOLN.US Molecular Partners AG ADR

Healthcare Biotechnology USA Stocks
2.94 USD
Close of Nov 15, 2026
2.63 5.36
Market cap
USD 113M
P/E
-
P/B
1.85x
ROE
-101.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MOLN.US undervalued?

Graham number

The Graham number of Molecular Partners AG ADR cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Molecular Partners AG ADR fundamental analysis

No fundamental analysis for Molecular Partners AG ADR yet.

Molecular Partners AG ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Molecular Partners AG ADR

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) …

Full company profile